Literature DB >> 22929325

Pharmacologic vitreolysis: rationale, potential indications, and promising agents.

Arnd Gandorfer1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22929325     DOI： 10.1097/IAE.0b013e31825bc4df

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  5 in total

Review 1.  Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion.

Authors:  Francisco R Stefanini; Maurício Maia; Paulo Falabella; Marcel Pfister; Moritz Niemeyer; Amir H Kashani; Mark S Humayun; Michael J Koss
Journal:  Clin Ophthalmol       Date:  2014-05-06

2.  Rhegmatogenous retinal detachment following intravitreal ocriplasmin.

Authors:  Haifa A Madi; Richard J Haynes; Diana Depla; Morten D de la Cour; Sarit Lesnik-Oberstein; Mahi M K Muqit; Niall Patton; Nick Price; David H W Steel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-08       Impact factor: 3.117

Review 3.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17

4.  Retinal breaks due to intravitreal ocriplasmin.

Authors:  Ruwan A Silva; Darius M Moshfeghi; Theodore Leng
Journal:  Clin Ophthalmol       Date:  2014-08-25

5.  Intravitreal injection associated rhegmatogenous retinal detachment: outcomes of a European analysis.

Authors:  Efstathios Vounotrypidis; Sigrid Freissinger; Matteo Cereda; Davide Monteduro; Karsten Kortuem; Siegfried Priglinger; Benjamin Mayer; Armin Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-07-03       Impact factor: 3.117
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.